Comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'

por Tougeron, D, Laurent-Puig, P, Zaanan, A
Publicado 2014

Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCEN...

por Taieb, J., Shi, Q., Pederson, L., Alberts, S., Wolmark, N., Van Cutsem, E., de Gramont, A., Kerr, R., Grothey, A., Lonardi, S., Yoshino, T., Yothers, G., Sinicrope, F.A., Zaanan, A., André, T.
Publicado 2019

Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study

por Tabernero, J., Shitara, K., Zaanan, A., Doi, T., Lorenzen, S., Van Cutsem, E., Fornaro, L., Catenacci, D.V.T., Fougeray, R., Moreno, S.R., Azcue, P., Arkenau, H.-T., Alsina, M., Ilson, D.H.
Publicado 2021

Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study

por Aparicio, T, Svrcek, M, Zaanan, A, Beohou, E, Laforest, A, Afchain, P, Mitry, Emmanuel, Taieb, J, Di Fiore, F, Gornet, J-M, Thirot-Bidault, A, Sobhani, I, Malka, D, Lecomte, T, Locher, C, Bonnetain, F, Laurent-Puig, P
Publicado 2013